Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 73.00K | 195.00K | 140.00K | 581.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 73.00K | 195.00K | 140.00K | 581.00K |
| Cost of Revenue | 1.60M | 2.54M | 8.05M | 8.31M | 10.56M |
| Gross Profit | -1.60M | -2.47M | -7.85M | -8.17M | -9.98M |
| SG&A Expenses | 7.98M | 6.68M | 6.60M | 8.80M | 6.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.58M | 9.22M | 14.65M | 17.11M | 16.97M |
| Operating Income | -9.58M | -9.15M | -14.46M | -16.97M | -16.39M |
| Income Before Tax | -8.85M | -13.04M | -13.46M | -15.68M | -15.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.85M | -13.04M | -13.46M | -15.68M | -15.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.85M | -13.04M | -13.46M | -15.68M | -15.03M |
| EBIT | -9.58M | -9.15M | -14.46M | -16.97M | -16.39M |
| EBITDA | -9.49M | -8.88M | -14.25M | -16.75M | -16.22M |
| EPS Basic | -4.86 | -7.15 | -7.39 | -8.62 | -8.27 |
| Normalized Basic EPS | -3.03 | -2.77 | -4.62 | -5.39 | -5.17 |
| EPS Diluted | -4.86 | -7.15 | -7.39 | -8.62 | -8.27 |
| Normalized Diluted EPS | -3.03 | -2.77 | -4.62 | -5.39 | -5.17 |
| Average Basic Shares Outstanding | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M |
| Average Diluted Shares Outstanding | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
